title: Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer.
abstract: Erythropoiesis-stimulating agents (ESAs) have been used for about three decades in chronic kidney disease patients to treat the symptoms of anemia, avoid potentially hazardous blood-product transfusions, improve some facets of quality of life, and reduce cardiovascular risk. We review a new article in which this association between stroke and ESA use is examined in a different population in a different way, but with the same worrying findings as seen in the TREAT study.
authors.affiliation: Renal and Transplantation Unit, Guy's Hospital, King's Health Partners AHSC, London, UK. david.goldsmith@gstt.nhs.uk
authors.forename: David J
authors.initials: DJ
authors.lastname: Goldsmith
authors.forename: Adrian C
authors.initials: AC
authors.lastname: Covic
mesh_terms: D000740:Anemia / Q000188:drug therapy*; D005260:Female; D006397:Hematinics / Q000009:adverse effects*; D006801:Humans; D007674:Kidney Diseases / Q000453:epidemiology*; D008297:Male; D020521:Stroke / Q000453:epidemiology*
chemical_list: D006397:Hematinics